216 related articles for article (PubMed ID: 20235886)
1. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.
Yu J; Henske EP
Lymphat Res Biol; 2010 Mar; 8(1):43-9. PubMed ID: 20235886
[TBL] [Abstract][Full Text] [Related]
2. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).
Kwiatkowski DJ
Lymphat Res Biol; 2010 Mar; 8(1):51-7. PubMed ID: 20235887
[TBL] [Abstract][Full Text] [Related]
3. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
6. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Krymskaya VP; McCormack FX
Annu Rev Med; 2017 Jan; 68():69-83. PubMed ID: 28099079
[TBL] [Abstract][Full Text] [Related]
7. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
8. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
[TBL] [Abstract][Full Text] [Related]
9. mTOR signaling in lymphangioleiomyomatosis.
Kristof AS
Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
[TBL] [Abstract][Full Text] [Related]
10. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.
Juvet SC; McCormack FX; Kwiatkowski DJ; Downey GP
Am J Respir Cell Mol Biol; 2007 Apr; 36(4):398-408. PubMed ID: 17099139
[TBL] [Abstract][Full Text] [Related]
12. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
14. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.
Li C; Lee PS; Sun Y; Gu X; Zhang E; Guo Y; Wu CL; Auricchio N; Priolo C; Li J; Csibi A; Parkhitko A; Morrison T; Planaguma A; Kazani S; Israel E; Xu KF; Henske EP; Blenis J; Levy BD; Kwiatkowski D; Yu JJ
J Exp Med; 2014 Jan; 211(1):15-28. PubMed ID: 24395886
[TBL] [Abstract][Full Text] [Related]
15. Lymphangioleiomyomatosis and TSC2-/- cells.
Darling TN; Pacheco-Rodriguez G; Gorio A; Lesma E; Walker C; Moss J
Lymphat Res Biol; 2010 Mar; 8(1):59-69. PubMed ID: 20235888
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N; Holz MK
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
[TBL] [Abstract][Full Text] [Related]
19. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
[TBL] [Abstract][Full Text] [Related]
20. Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice.
Lesma E; Eloisa C; Isaia E; Grande V; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
Am J Pathol; 2012 Sep; 181(3):947-60. PubMed ID: 22770663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
